RhumbLine Advisers’s Harvard Bioscience HBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
Sell
-41,396
Closed -$23.4K 4189
2025
Q1
$23.4K Buy
41,396
+1,959
+5% +$1.11K ﹤0.01% 3714
2024
Q4
$83.2K Buy
39,437
+710
+2% +$1.5K ﹤0.01% 3522
2024
Q3
$104K Sell
38,727
-9,026
-19% -$24.3K ﹤0.01% 3485
2024
Q2
$136K Buy
47,753
+9,512
+25% +$27.1K ﹤0.01% 3410
2024
Q1
$162K Buy
38,241
+1,661
+5% +$7.04K ﹤0.01% 3268
2023
Q4
$196K Sell
36,580
-117
-0.3% -$626 ﹤0.01% 3196
2023
Q3
$158K Buy
36,697
+2,141
+6% +$9.21K ﹤0.01% 3279
2023
Q2
$190K Buy
+34,556
New +$190K ﹤0.01% 3263
2022
Q2
Sell
-36,190
Closed -$225K 3151
2022
Q1
$225K Buy
36,190
+11,518
+47% +$71.6K ﹤0.01% 2729
2021
Q4
$174K Sell
24,672
-635
-3% -$4.48K ﹤0.01% 2862
2021
Q3
$177K Buy
25,307
+1,800
+8% +$12.6K ﹤0.01% 2927
2021
Q2
$196K Sell
23,507
-19,487
-45% -$162K ﹤0.01% 2925
2021
Q1
$235K Sell
42,994
-1,340
-3% -$7.32K ﹤0.01% 2784
2020
Q4
$190K Buy
44,334
+8,066
+22% +$34.6K ﹤0.01% 2856
2020
Q3
$109K Sell
36,268
-8,055
-18% -$24.2K ﹤0.01% 2850
2020
Q2
$137K Buy
+44,323
New +$137K ﹤0.01% 2884
2019
Q2
Sell
-48,643
Closed -$210K 2985
2019
Q1
$210K Sell
48,643
-265
-0.5% -$1.14K ﹤0.01% 2731
2018
Q4
$156K Buy
48,908
+15,839
+48% +$50.5K ﹤0.01% 2802
2018
Q3
$174K Buy
33,069
+2,384
+8% +$12.5K ﹤0.01% 2773
2018
Q2
$164K Buy
+30,685
New +$164K ﹤0.01% 2783
2016
Q2
Sell
-42,058
Closed -$127K 2997
2016
Q1
$127K Buy
42,058
+4,725
+13% +$14.3K ﹤0.01% 2855
2015
Q4
$130K Buy
37,333
+1,915
+5% +$6.67K ﹤0.01% 2913
2015
Q3
$134K Buy
35,418
+2,358
+7% +$8.92K ﹤0.01% 2896
2015
Q2
$188K Buy
+33,060
New +$188K ﹤0.01% 2911
2014
Q2
Sell
-32,137
Closed -$152K 3033
2014
Q1
$152K Sell
32,137
-1,250
-4% -$5.91K ﹤0.01% 2855
2013
Q4
$157K Sell
33,387
-13,486
-29% -$63.4K ﹤0.01% 2888
2013
Q3
$187K Buy
46,873
+48
+0.1% +$191 ﹤0.01% 2810
2013
Q2
$168K Buy
+46,825
New +$168K ﹤0.01% 3070